Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Melanocortin Receptor 4 (MC4R) - Overview Melanocortin Receptor 4 (MC4R) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Melanocortin Receptor 4 (MC4R) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Melanocortin Receptor 4 (MC4R) - Companies Involved in Therapeutics Development AstraZeneca Plc MallInckrodt Plc Palatin Technologies Inc Melanocortin Receptor 4 (MC4R) - Drug Profiles (liraglutide + setmelanotide) - Drug Profile Product Description Mechanism Of Action R&D Progress AQB-565 - Drug Profile Product Description Mechanism Of Action R&D Progress bremelanotide - Drug Profile Product Description Mechanism Of Action R&D Progress corticotropin - Drug Profile Product Description Mechanism Of Action R&D Progress PL-8905 - Drug Profile Product Description Mechanism Of Action R&D Progress setmelanotide - Drug Profile Product Description Mechanism Of Action R&D Progress setmelanotide ER - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Agonize MC4-R for Obesity - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Antagonize Melanocortin-4 Receptor for Cachexia - Drug Profile Product Description Mechanism Of Action R&D Progress Synthetic Peptide to Agonize Melanocortin 4 Receptor for Diabetes, Obesity, Female Sexual Dysfunction and Erectile Dysfunction - Drug Profile Product Description Mechanism Of Action R&D Progress Melanocortin Receptor 4 (MC4R) - Dormant Products Melanocortin Receptor 4 (MC4R) - Discontinued Products Melanocortin Receptor 4 (MC4R) - Product Development Milestones Featured News & Press Releases Jan 30, 2018: First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar Gel (Repository Corticotropin Injection) for Pulmonary Sarcoidosis Jan 04, 2018: Rhythm Pharmaceuticals Announces Progress in Clinical Development of Setmelanotide for Treatment of Rare Genetic Disorders of Obesity Dec 04, 2017: Mallinckrodt plc Presents Health Economic Data on Management of Infantile Spasms at American Epilepsy Society Annual Meeting Oct 31, 2017: Rhythm Announces Preliminary Data from Phase 2 Study of Setmelanotide for Treatment of Bardet-Biedl Syndrome Oct 26, 2017: Mallinckrodt Presents Multiple Sclerosis Relapse Data at 7th Joint ECTRIMS-ACTRIMS Meeting (MSParis2017) Oct 09, 2017: Mallinckrodt Statement on October 7, 2017, CHEST Journal Article Oct 09, 2017: Mallinckrodt Will Conduct Phase 4 Trial of H.P. Acthar Gel (Repository Corticotropin Injection) for Symptomatic Sarcoidosis Sep 12, 2017: Open Letter to Mallinckrodt Employees, Customers and Patients Reinforcing Important Facts Related to H.P. Acthar Gel and Other Matters Jul 31, 2017: Summary Review of Clinical and Economic Data on H.P. Acthar Gel Published in Advances in Therapy Jul 25, 2017: Mallinckrodt Posts Data From Legacy H.P. Acthar Gel (Repository Corticotropin Injection) Pilot Study To clinicaltrials.gov Jun 27, 2017: Rhythm and Camurus Announce Positive Initial Data for Extended-Release Delivery of Setmelanotide for the Treatment of Rare Genetic Disorders of Obesity Jun 26, 2017: MNK H.P. Acthar Gel DN Trial Results Alert Jun 22, 2017: Mallinckrodt Statement on H.P. Acthar Gel Update Jun 14, 2017: Mallinckrodt Enrolls First Patient in Phase 2B Trial of H.P. Acthar Gel (Repository Corticotropin Injection) for Amyotrophic Lateral Sclerosis Jun 06, 2017: Mallinckrodt Updates Facts Refuting Short-Seller Claims Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Therapy Areas, H1 2018 Number of Products under Development by Indication, H1 2018 Number of Products under Development by Companies, H1 2018 Products under Development by Companies, H1 2018 Number of Products under Investigation by Universities/Institutes, H1 2018 Products under Investigation by Universities/Institutes, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Stage and Route of Administration, H1 2018 Number of Products by Stage and Molecule Type, H1 2018 Pipeline by AstraZeneca Plc, H1 2018 Pipeline by MallInckrodt Plc, H1 2018 Pipeline by Palatin Technologies Inc, H1 2018 Dormant Products, H1 2018 Dormant Products, H1 2018 (Contd..1), H1 2018 Discontinued Products, H1 2018List of Figures Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Therapy Areas, H1 2018 Number of Products under Development by Top 10 Indications, H1 2018 Number of Products by Mechanism of Actions, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Routes of Administration, H1 2018 Number of Products by Stage and Routes of Administration, H1 2018 Number of Products by Molecule Types, H1 2018 Number of Products by Stage and Molecule Types, H1 2018